Insights

Innovative Therapeutics Xintela specializes in stem cell therapy and targeted cancer treatments based on its proprietary integrin α10β1 marker, offering unique opportunities for partnerships in regenerative medicine and oncology drug development.

Clinical Development Focus With products like XSTEM® progressing through clinical trials for knee osteoarthritis and leg ulcers, there is potential to collaborate on clinical research, manufacturing, and regulatory support for advanced cell therapies.

Strategic Collaborations Recent partnerships with financial advisors and key personnel appointments suggest an openness to strategic alliances and funding opportunities, ideal for expanding commercialization efforts and research collaborations.

Expanding Innovation Patents around quality-assured chondrocytes indicate a strong focus on intellectual property, providing opportunities to license or co-develop proprietary cell-based products in orthopedic and cartilage repair markets.

Market Entry Potential Operating with a small but focused team in biotech research and development, Xintela offers a nimble partner profile ideal for joint ventures, pilot programs, or early-stage collaborations to access emerging regenerative and cancer therapeutics markets.

Xintela AB Email Formats	Example	Percentage
First.Last@xintela.se	John.Doe@xintela.se	37%
First@xintela.se	John@xintela.se	19%
Last@xintela.se	Doe@xintela.se	7%
First.Last@xintela.se	John.Doe@xintela.se	37%

Xintela AB Email Formats

Example

Percentage

First.Last@xintela.se

John.Doe@xintela.se

37%

First@xintela.se

John@xintela.se

19%

Last@xintela.se

Doe@xintela.se

First.Last@xintela.se

John.Doe@xintela.se

37%

Frequently Asked Questions

Where is Xintela AB's headquarters located?

Xintela AB's main headquarters is located at Scheelevägen, Lund, Skåne 22381, SE. The company has employees across 1 continents, including Europe.

What is Xintela AB's phone number?

You can contact Xintela AB's main corporate office by phone at

+46-70-329-1****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Xintela AB's official website and social media links?

Xintela AB's official website is xintela.se and has social profiles on LinkedIn Crunchbase.

What is Xintela AB's SIC code NAICS code?

Xintela AB's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Xintela AB have currently?

As of October 2025, Xintela AB has approximately 19 employees across 1 continents, including Europe. Key team members include Ceo: E. L.Ceo: E. L.Coo & Vp Commercial Manufacturing: P. E.. Explore Xintela AB's employee directory with LeadIQ.

What industry does Xintela AB belong to?

Xintela AB operates in the Biotechnology Research industry.

What technology does Xintela AB use?

Xintela AB's tech stack includes jQueryAdobe Fonts.

What is Xintela AB's email format?

Xintela AB's email format typically follows the pattern of First.Last@xintela.se. Find more Xintela AB email formats with LeadIQ.

When was Xintela AB founded?

Xintela AB was founded in 2009.

Xintela AB

Q: What is Xintela AB's official website and social media links?

Xintela AB's official website is xintela.se. Xintela AB has social profiles on LinkedIn.

Q: How many employees does Xintela AB have currently?

Xintela AB has approximately 19 employees.

Q: What technology does Xintela AB use?

Xintela AB's tech stack includes Adobe Fonts, jQuery.

Biotechnology ResearchSweden11-50 Employees

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.

Insights

Similar companies to Xintela AB

Rubius Therapeutics

Vertex Pharmaceuticals

Cellectis

Editas Medicine

bluebird bio

CRISPR Therapeutics

Xintela AB Tech Stack

Media & News

Xintela AB hires Lucienne Vonk as Chief Scientific Officer.

Xintela AB partners with Carnegie Investment Bank AB.

Xintela AB hired Lars Hedbys as Board of Directors on Nov 12th '20.

Xintela AB launches PCT) patent application for quality-assured chondrocytes.

Xintela AB's Email Address Formats